Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…


The choroid plexus: where inflammation meets neurology

We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce you to Roosmarijn Van…

POPULAR TAGS

Apitope receives 12 million euros from Wales

Written by DS on in the category news with the tags , , .


The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an investor in Wales. It concerns the Wales Life Sciences Fund, which became a shareholder of Apitope during the capital increase.

The current shareholders of Apitope also participated in the financing round, including investment funds like Vesalius Biocapital, LRM and PMV. It is unclear how much they invested.

Apitope works on treatments for autoimmune diseases such as multiple sclerosis (MS), Graves' disease (thyroid), Factor VIII intolerance (bleeding disorder or hemophilia), and unveitis (eye inflammation). The MS research is the most advanced, but was licensed in 2009 to Merck Serono. Apitope will possibly receive a part of the turnover of the MS product.

Apitope will deploy the extra budget to further develop the treatments for Graves' disease and Factor VIII intolerance. The latter product recently received recognition as an orphan drug for hemophilia. Apitope assumes that it gains access to a market of 3.5 billion euros

Read more about: , , .

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…


The choroid plexus: where inflammation meets neurology

We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce you to Roosmarijn Van…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin GSK KU Leuven Janssen Flanders.bio UGent XpandInnovation Turnstone V-Bio Ventures Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.